This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
This is an open label study. All patients prescribed with Doxazosin GITS can be enrolled in this study.
Study Type
OBSERVATIONAL
Enrollment
989
Doxazosin mesylate GITS 4mg to 8mg once daily
Number of Participants With Adverse Events (AEs)
Any untoward medical occurrence in a participant who received study drug was considered an AE, without regard to possibility of causal relationship.
Time frame: Baseline up to Week 13 (7 days after last dose)
Percent Change From Baseline in the International Prostate Symptom (IPSS) Total Score at Week 4 and Week 12
The IPSS total score is obtained by combining the scores of the responses to 1 through 7 component questions all of which were on a 6 point likert scale. Each question is scored from 0-5 for an IPSS range of 0-35 points where 0 = best possible score to 35 = worst possible score.
Time frame: Baseline, Week 4 and Week 12
Percent Change From Baseline in the IPSS Quality of Life (QoL) Score at Week 4 and Week 12
The IPSS QoL Score is obtained by assessment of a single QoL question on a 7-point likert scale which was scored on a scale of 0-6 where 0 = best possible score to 6 = worst possible score.
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Systolic BP at Week 4 and Week 12
Values at Week 4 and Week 12 minus value at baseline.
Time frame: Baseline through Week 12
Change From Baseline in Diastolic BP at Week 4 and Week 12
Values at Week 4 and Week 12 minus value at baseline.
Time frame: Baseline through Week 12
Percentage of Participants With Postural Hypotension
Postural or orthostatic hypotension is a medical condition where blood pressure falls rapidly after the body changes position most commonly occurring after standing up after sitting for long periods of time.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Butuan, Agusan Del Norte, Philippines
Pfizer Investigational Site
San Juan City, Batangas, Philippines
Pfizer Investigational Site
Tagbilaran City, Bohol, Philippines
Pfizer Investigational Site
Quezon City, Diliman, Philippines
Pfizer Investigational Site
City of San Fernando, La Union, Philippines
Pfizer Investigational Site
Ermita, Manila, Philippines
Pfizer Investigational Site
Tondo, Manila, Philippines
Pfizer Investigational Site
Diliman, Quezon City, National Capital Region, Philippines
Pfizer Investigational Site
Pasig, National Capital Region, Philippines
Pfizer Investigational Site
Angeles City, Pampanga, Philippines
...and 57 more locations
Time frame: Baseline up to Week 13 (7 days after last dose)